BofA lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $563 from $565 and keeps a Buy rating on the shares. The firm, which expects steady growth for the cystic fibrosis franchise in Q3, remains “bullish” on the strong commercial performance of the CF franchise and multiple shots on goal across the portfolio, the analyst tells investors in a preview.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Strong Market Position and Growth Potential Reinforce Buy Rating
- Vertex Pharmaceuticals announces updates across program for povetacicept
- Vertex Pharmaceuticals price target lowered to $438 from $439 at Morgan Stanley
- Vertex Pharmaceuticals: Strong Growth Potential with Promising Product Launches and Robust Pipeline
- Vertex Pharmaceuticals price target raised to $575 from $550 at Citi